慢性心力衰竭患者血清AFABP、PARP1、GRP78、IGFBP-7水平与其临床分型、预后的关系

doi:10.3969/j.issn.1006-5725.2026.10.009

Abstract

Abstract:

Objective To explore the relationship between the levels of serum adipocyte fatty acid binding protein （AFABP）， polyadenosine diphosphate ribose polymerase 1 （PARP1）， glucose-regulated protein 78 （GRP78）， and insulin-like growth factor binding protein-7 （IGFBP-7） in patients with chronic heart failure （CHF）， and the relationship between these levels and their clinical classification and prognosis. Methods A total of 259 patients with CHF who were admitted to our hospital from January 2023 to January 2025 （CHF group） and 259 healthy individuals with age- and gender-matching who underwent physical examinations during the same period （control group） were selected. According to the cardiac function classification of the New York Heart Association （NYHA）， CHF patients were divided into grade II （106 cases）， grade III （91 cases）， and grade IV （62 cases）. CHF patients were classified into three clinical subtypes based on left ventricular ejection fraction （LVEF）， namely the heart failure with preserved ejection fraction （HFpEF， LVEF ≥ 50%）， the heart failure with mildly reduced ejection fraction （HFmrEF， LVEF 41% - 49%）， and the heart failure with reduced ejection fraction （HFrEF， LVEF ≤ 40%）， with 114 cases， 91 cases， and 54 cases respectively. These subtypes are respectively referred to as the preservation group， the mild-reduction group， and the reduction group. After the treatment， a 6-month follow-up was carried out. During the follow-up period， 11 cases were lost to follow-up， while a total of 248 cases successfully completed the follow-up. Based on the occurrence of major adverse cardiac events （MACE， including cardiac death or rehospitalization due to heart failure）， the cases were divided into the poor prognosis group （64 cases） and the good prognosis group （184 cases）. The clinical data of all the research subjects were statistically analyzed， and the levels of serum AFABP， PARP1， GRP78， and IGFBP-7 in CHF patients with different cardiac function grades and clinical types were compared among the CHF group， the control group， the poor prognosis group， and the good prognosis group. Spearman correlation analysis was employed to examine the correlations between the levels of serum AFABP， PARP1， GRP78， and IGFBP-7 and the NYHA cardiac function classification and clinical typing. Multivariate logistic regression analysis was utilized to identify the risk factors for poor prognosis in patients with CHF. The predictive efficacy of the combined detection of serum AFABP， PARP1， GRP78， and IGFBP-7 levels for the poor prognosis of CHF patients was evaluated by the receiver operating characteristic curve （ROC）. Results The levels of serum AFABP， PARP1， GRP78， and IGFBP-7 in the CHF group were significantly higher than those in the control group （P < 0.05）. As the NYHA cardiac function classification deteriorated （from grade II to grade IV） and the LVEF decreased （from HFpEF to HFrEF）， the levels of each index exhibited a gradually increasing trend （P < 0.05）. Spearman analysis indicated that the levels of serum AFABP， PARP1， GRP78， and IGFBP-7 were positively correlated with the NYHA cardiac function classification （r = 0.652， 0.570， 0.631， 0.588， P < 0.05） and also positively correlated with the patient's clinical classification （r = 0.496， 0.768， 0.601， 0.608， P < 0.05）. There were statistically significant differences in the levels of serum AFABP， PARP1， GRP78， and IGFBP-7， as well as the proportion of cardiac function classification and clinical classification， between the poor-prognosis group and the good-prognosis group （P < 0.05）. The results of multivariate logistic regression analysis showed that a worse cardiac function classification （OR = 3.086， 95%CI： 1.376 - 6.921）， the HFrEF phenotype （OR = 3.647， 95%CI： 1.921 - 6.923）， a high AFABP level （OR = 2.675， 95% CI 1.248 - 5.734）， a high PARP1 level （OR = 2.713， 95%CI： 1.298 - 5.669）， a high GRP78 level （OR = 2.492， 95%CI： 1.113 - 5.576）， and a high IGFBP-7 level （OR = 2.237， 95%CI： 1.158 - 4.321） were all risk factors for poor prognosis in CHF patients （all P < 0.05）. After drawing the ROC curve， it was found that the combined detection of serum AFABP， PARP1， GRP78， and IGFBP-7 levels had an AUC value for the poor prognosis of CHF patients （0.936， 95%CI： 0.898 - 0.963）， which was higher than that of individual detection of each index （P < 0.05）. The sensitivity and specificity of the combined detection were 90.62% and 80.43%， respectively. Conclusions The levels of AFABP， PARP1， GRP78， and IGFBP-7 are highly expressed in the serum of patients with CHF. These levels are closely related to the cardiac function classification and clinical type of CHF patients. A worse cardiac function classification， the HFrEF phenotype， high levels of AFABP， PARP1， GRP78， and IGFBP-7 are all risk factors for the poor prognosis of CHF patients. The combined detection of AFABP， PARP1， GRP78， and IGFBP-7 has high predictive value for the poor prognosis of CHF patients and is expected to become a new biomarker combination for evaluating the condition and prognosis of CHF.

Key words: chronic heart failure, adipocyte type fatty acid binding protein, polyadenylate diphosphate ribose polymerase 1, glucose-regulated protein 78, insulin-like growth factor binding protein-7, prognosis

CLC Number:

R541.61

Lunlun LI,Linlin YANG,Lijuan WANG. Analysis of the relationship between the levels of serum AFABP， PARP1， GRP78 and IGFBP-7 in patients with chronic heart failure and their clinical classification and prognosis[J]. The Journal of Practical Medicine, 2026, 42(10): 1752-1761.

Figures/Tables 10

Tab.1

Clinical features"

临床特征	CHF组（n = 259）	对照组（n = 259）	χ²/t值	P值
年龄（ $x ˉ ? ± ? s$ ）/岁	63.14±5.44	62.71±5.82	0.869	0.385
性别			0.502	0.478
男	150（57.92）	142（54.83）
女	109（42.08）	117（45.17）
BMI（ $x ˉ ? ± ? s$ ）/（kg/m²）	23.60 ± 1.43	23.42 ± 1.58	1.359	0.175
心功能分级			-	-
Ⅱ级	106（40.93）	-
Ⅲ级	91（35.14）	-
Ⅳ级	62（23.94）	-
临床分型			-	-
保留组	114（44.02）	-
临界组	91（35.14）	-
减低组	54（20.85）	-

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Tab.6

Univariate analysis of the prognosis of CHF patients 例（%）"

因素	预后不良组（n = 64）	预后良好组（n = 184）	χ² /t值	P值
年龄（ $x ˉ ? ± ? s$ ）/岁	64.87 ± 5.97	62.95 ± 5.28	3.877	< 0.001
性别			2.033	0.154
男	41（64.06）	99（53.80）
女	23（35.94）	85（46.20）
BMI（ $x ˉ ? ± ? s$ ）/（kg/m²）	23.77 ± 1.53	23.50 ± 1.48	1.246	0.214
心功能分级			10.838	0.004
Ⅱ级	16（25.00）	89（48.37）
Ⅲ级	27（42.19）	57（30.98）
Ⅳ级	21（32.81）	38（20.65）
临床分型			7.665	0.022
保留组	19（29.69）	90（48.91）
临界组	26（40.63）	60（32.61）
减低组	19（29.69）	34（18.48）
AFABP（ $x ˉ ? ± ? s$ ）/（ng/mL）	256.21 ± 81.10	210.86 ± 57.95	4.832	< 0.001
PARP1（ $x ˉ ? ± ? s$ ）/（μg/L）	9.16 ± 2.85	7.25 ± 2.29	5.382	< 0.001
GRP78（ $x ˉ ? ± ? s$ ）/（ng/mL）	470.22 ± 134.38	363.76 ± 115.30	10.590	< 0.001
IGFBP-7（ $x ˉ ? ± ? s$ ）/（μg/L）	74.26 ± 21.79	63.58 ± 19.18	3.702	< 0.001

Tab.6

Tab.7

Tab.8

Tab.9

Fig.1

References 27

[1]	CIUCA-PANĂ M A， BOULMPOU A， ILERI C， et al. Chronic Heart Failure and Coronary Artery Disease： Pharmacological Treatment and Cardiac Rehabilitation［J］. Med，2025， 61（2）： 211. doi： 10.3390/medicina61020211 . doi: 10.3390/medicina61020211
[2]	POWRÓZEK T， SKWAREK-DZIEKANOWSKA A， SOBIESZEK G， et al. Correlation between Neutrophil-to-Lymphocyte Ratio， Platelets-to-Lymphocyte Ratio， C-Reactive Protein-to-Albumin Ratio and Clinical Picture of Elderly Chronic Heart Failure Patients［J］. J Clin Med， 2024， 13（2）： 433. doi： 10.3390/jcm13020433 . doi: 10.3390/jcm13020433
[3]	HEIDENREICH P A， BOZKURT B， AGUILAR D， et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure： A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines［J］. Circ，2022， 145（18）： 895-1032. doi： 10.1161/CIR.0000000000001063 . doi: 10.1161/CIR.0000000000001063
[4]	LI N， HAN J X. Research progress of mhr， rdw， d-dimer/fib and vascular endothelial function in chronic heart failure［J］. Clin Med Insights Cardiol， 2022， 12（6）： 843-850. doi： 10.12677/acm.2022.126843 . doi: 10.12677/acm.2022.126843
[5]	LI B， ZAMZAM A， SYED M H， et al. Fatty acid binding protein 4 has prognostic value in peripheral artery disease［J］. J Vasc Surg， 2023， 78（3）： 719-726. doi： 10.1016/j.jvs.2023.03.096 . doi: 10.1016/j.jvs.2023.03.096
[6]	SHU J， YAN S， JU C， et al. PARP1 Promotes Heart Regeneration and Cardiomyocyte Proliferation［J］. Int J Biol Sci， 2024， 20（5）： 1602-1616. doi： 10.7150/ijbs.85526 . doi: 10.7150/ijbs.85526
[7]	SHI C， ZHANG Q， LI Y， et al. Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2alpha pathway， and improves cardiac injury by suppressing TLR4/NF-kappaB inflammatory pathway［J］. BMC Cardiovasc Disord，2024， 24（1）： 704. doi： 10.1186/s12872-024-04427-4 . doi: 10.1186/s12872-024-04427-4
[8]	ADAMSON C， WELSH P， DOCHERTY K F， et al. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction： Findings From DAPA-HF［J］. JACC Heart Fail， 2023， 11（3）： 291-304. doi： 10.1016/j.jchf.2022.09.004 . doi: 10.1016/j.jchf.2022.09.004
[9]	NAHLER M P G. New york heart association classification （NYHA）［M］. Vienna： Springer Verlag， 2009： 143-149. doi： 10.1007/978-3-211-89836-9_911 . doi: 10.1007/978-3-211-89836-9_911
[10]	MCDONAGH T A， METRA M， ADAMO M， et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure［J］. Eur Heart J， 2021， 42（36）： 3599-3726.doi：10.1093/eurjhf/hfn030 . doi: 10.1093/eurjhf/hfn030
[11]	中华医学会，中华医学会杂志社，中华医学会全科医学分会，等. 慢性心力衰竭基层诊疗指南（2019 年）［J］. 中华全科医师杂志， 2019， 18（10）： 936-947. doi： 10.3760/cma.j.issn.1671-7368.2019.10.008 . doi: 10.3760/cma.j.issn.1671-7368.2019.10.008
[12]	ADAMO M， CHIONCEL O， PAGNESI M， et al. Epidemiology， pathophysiology， diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association （HFA） and the European Association of Percutaneous Cardiovascular Interventions （EAPCI） of the ESC［J］. Eur J Heart Fail，2024，26（1）：18-33. doi： 10.1002/ejhf.3106 . doi: 10.1002/ejhf.3106
[13]	MASCOLO A， DI MAURO G， CAPPETTA D， et al. Current and future therapeutic perspective in chronic heart failure［J］. Pharmacol Res，2022，175：106035. doi： 10.1016/j.phrs.2021.106035 . doi: 10.1016/j.phrs.2021.106035
[14]	WANG C， GE J B， ZHANG Y， et al. Multidisciplinary management of chronic heart failure complicated with chronic obstructive pulmonary disease： an expert consensus［J］. Chest， 2025， 168（6）： 2215-2228. doi： 10.1164/rccm.202407-1320ST . doi: 10.1164/rccm.202407-1320ST
[15]	SACCO S， PONIKOWSKI P， VOORS A A， et al. Quadruple therapy for chronic heart failure： Updated evidence and clinical practice recommendations［J］. Eur Heart J， 2024， 45（32）： 2890-2901. doi： 10.1002/ehf2.14857 . doi: 10.1002/ehf2.14857
[16]	季润青，张丽华，黄星荷，等. 不同左心室射血分数心力衰竭住院患者的临床特征，诊疗情况及结局差异［J］. 中国循环杂志， 2021， 36（8）： 769-774. doi： 10.3969/j.issn.1000-3614.2021.08.007 . doi: 10.3969/j.issn.1000-3614.2021.08.007
[17]	DUBIN R F， DEO R， REN Y， et al. Investigators. Incident heart failure in chronic kidney disease： Proteomics informs biology and risk stratification［J］. Eur Heart J， 2024， 45（30）： 2752-2767. doi： 10.1093/eurheartj/ehae288 . doi: 10.1093/eurheartj/ehae288
[18]	杨凯同，和丽丽，左庆娟，等. 慢性心力衰竭患者血清脯氨酸脱氢酶水平与左心收缩功能的关联性分析［J］. 吉林大学学报（医学版）， 2024， 50（6）： 1719-1727. doi： 10.13481/j.1671-587X.20240626 . doi: 10.13481/j.1671-587X.20240626
[19]	LIU X， CHEN L， YANG H， et al. Novel biomarkers for prognosis assessment in chronic heart failure： a systematic review and meta-analysis［J］. J Card Fail， 2023， 29（8）： 1123-1135. doi： 10.1186/s12872-025-04704-w . doi: 10.1186/s12872-025-04704-w
[20]	LEE C H， KAN A K C， LUI D T W， et al. Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes［J］. ESC Heart Fail， 2021， 8（5）： 3964-3974. doi： 10.1007/s00395-022-00925-8 . doi: 10.1007/s00395-022-00925-8
[21]	WANG Z， QIU Z， HUA S， et al. Nuclear Tkt promotes ischemic heart failure via the cleaved Parp1/Aif axis［J］. Basic Res Cardiol， 2022， 117（1）： 18. doi： 10.1016/j.heliyon.2023.e13436 . doi: 10.1016/j.heliyon.2023.e13436
[22]	ZHAO X， ZHANG D Q， SONG R， et al. The clinical significance of circulating glucose-regulated protein 78， Caspase-3， and C/EBP homologous protein levels in patients with heart failure［J］. Heliyon， 2023， 9（2）： 13436. doi： 10.1016/j.heliyon.2023.e13436 . doi: 10.1016/j.heliyon.2023.e13436
[23]	FERREIRA J P， PACKER M， SATTAR N， et al. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure： Results from the EMPEROR programme［J］. Eur J Heart Fail， 2024， 26（4）： 806-816. doi： 10.1002/ejhf.3227 . doi: 10.1002/ejhf.3227
[24]	TAN E S J， CHAN S P， CHOI Y C， et al. Regional handling and prognostic performance of circulating insulin-like growth factor binding protein-7 in heart failure［J］. JACC Heart Fail， 2023， 11（6）： 662-674. doi： 10.1016/j.jchf.2023.01.016 . doi: 10.1016/j.jchf.2023.01.016
[25]	PANICHELLA G， TOMASONI D， AIMO A， et al. Insulin-like growth factor binding protein-7 in heart failure： The challenge of moving from risk prediction to a biomarker-guided management［J］. Eur J Heart Fail， 2024， 26（8）： 1827-1829. doi： 10.1002/ejhf.3287 . doi: 10.1002/ejhf.3287
[26]	YAMASHITA S， BU X， ISHIWATA-ENDO H， et al. A PARP inhibitor， rucaparib， improves cardiac dysfunction in ADP-ribose-acceptor hydrolase 3 （Arh3） deficiency［J］. BioRxiv， 2023， 7（1）： 2023. doi： 10.1101/2023.02.07.527369 . doi: 10.1101/2023.02.07.527369
[27]	徐亚萍，单燕，陆秋英，等. 血清Ang-2， PARP1，hs-CRP/PAB比值在老年心力衰竭并发心律失常患者中的变化及与预后的关系［J］. 哈尔滨医科大学学报， 2025， 3（59）： 294-299. doi： 10.20010/j.issn.1000-1905.2025.03.0294 . doi: 10.20010/j.issn.1000-1905.2025.03.0294

指标	CHF组（n = 259）	对照组（n = 259）	t值	P值
AFABP/（ng/mL）	245.01 ± 66.37	25.05 ± 7.55	52.994	< 0.001
PARP1/（μg/L）	8.61 ± 2.64	3.97 ± 1.13	26.004	< 0.001
GRP78/（ng/mL）	429.11 ± 105.12	285.83 ± 84.62	17.087	< 0.001
IGFBP-7/（μg/L）	68.93 ± 21.85	44.67 ± 11.22	15.895	< 0.001

指标	心功能分级			F值	P值
指标	Ⅱ级（n = 106）	Ⅲ级（n = 91）	Ⅳ级（n = 62）	F值	P值
AFABP/（ng/mL）	192.64 ± 59.26	230.73 ± 68.36^*	313.29 ± 83.96^*#	60.034	< 0.001
PARP1/（μg/L）	6.93 ± 2.13	8.99 ± 2.82^*	9.89 ± 2.36^*#	33.258	< 0.001
GRP78/（ng/mL）	375.21 ± 89.75	428.85 ± 96.38^*	484.28 ± 98.57^*#	26.785	< 0.001
IGFBP-7/（μg/L）	52.28 ± 15.54	67.17 ± 21.84^*	87.65 ± 23.28^*#	62.063	< 0.001

指标	临床分型			F值	P值
指标	减低组（n = 54）	临界组（n = 91）	保留组（n = 114）	F值	P值
AFABP/（ng/mL）	311.48 ± 86.53^*#	221.58 ± 66.03^*	205.27 ± 63.12	44.626	< 0.001
PARP1/（μg/L）	9.66 ± 2.88^*#	9.31 ± 3.04^*	6.88 ± 2.17	29.989	< 0.001
GRP78/（ng/mL）	553.28 ± 125.03^*#	413.19 ± 107.35^*	322.97 ± 89.77	90.323	< 0.001
IGFBP-7/（μg/L）	80.38 ± 20.52^*#	71.84 ± 22.46^*	53.95 ± 16.90	39.436	< 0.001

自变量	变量性质	赋值方法
CHF	Y	0=无，1=有
心功能分级	X₁	0=Ⅱ级，1=Ⅲ级，2=Ⅳ级
临床分型	X₂	0=保留组，1=临界组，2=减低组
AFABP/（ng/mL）	X₃	原值输入
PARP1/（μg/L）	X₄	原值输入
GRP78/（ng/mL）	X₅	原值输入
IGFBP-7/（μg/L）	X₆	原值输入

多因素	β	SE	Wald χ²	P值	OR	95%CI
心功能分级	1.127	0.412	7.483	0.006	3.086	1.376 ~ 6.921
HFrEF表型	1.294	0.327	15.659	< 0.001	3.647	1.921 ~ 6.923
AFABP水平	0.984	0.389	6.399	0.011	2.675	1.248 ~ 5.734
PARP1水平	0.998	0.376	7.045	0.008	2.713	1.298 ~ 5.669
GRP78水平	0.913	0.411	4.935	0.026	2.492	1.113 ~ 5.576
IGFBP-7水平	0.805	0.336	5.740	0.017	2.237	1.158 ~ 4.321

Analysis of the relationship between the levels of serum AFABP， PARP1， GRP78 and IGFBP-7 in patients with chronic heart failure and their clinical classification and prognosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 27

Related Articles 15

Recommended Articles

Metrics

Comments

指标	NYHA心功能分级		临床分型
指标	r值	P值	r值	P值
AFABP	0.652	< 0.001	0.496	0.012
PARP1	0.570	0.009	0.768	< 0.001
GRP78	0.631	< 0.001	0.601	0.006
IGFBP-7	0.588	0.003	0.608	< 0.001

指标	敏感度/%	特异度/%	AUC	95%CI	截断值	P值
AFABP/（ng/mL）	62.50	69.02	0.658^*	0.595 ~ 0.717	234.21	< 0.001
PARP1/（μg/L）	75.00	61.41	0.707^*	0.646 ~ 0.763	7.81	< 0.001
GRP78/（ng/mL）	64.06	81.52	0.759^*	0.701 ~ 0.811	449.83	< 0.001
IGFBP-7/（μg/L）	65.62	68.48	0.685^*	0.624 ~ 0.743	70.62	< 0.001
联合	90.62	80.43	0.936	0.898 ~ 0.963	12.00	< 0.001

[1]	Qiuhong LIN,Chunguang DONG,Jiahui HAN,Hongpeng DONG,Shujia ZHANG. The prognostic value of p16 protein expression in predicting outcomes of comprehensive treatment for locally advanced laryngeal and hypopharyngeal carcinoma [J]. The Journal of Practical Medicine, 2026, 42(9): 1545-1551.
[2]	Li XIANG,Yijuan JIA,Ping WANG,Yanqin LOU,Donghua WANG. The predictive value of sCD276，YKL-40，miR-152-5p and miR-193a-5p in the prognosis of patients with high-grade serous ovarian cancer [J]. The Journal of Practical Medicine, 2026, 42(8): 1428-1434.
[3]	Yahong NIE,Meiyu ZHAO,Chengyu SHI,Shan LIU. The relationship between serum miR-145， miR-934， AFP， TK1 levels and clinicopathological characteristics and prognosis in patients with primary liver cancer [J]. The Journal of Practical Medicine, 2026, 42(7): 1183-1191.
[4]	Fengxue DAI,Zhenfei WANG. Predictive analysis of serum COL10A1， miRNA-21 and miRNA-320c expression levels for peritoneal metastasis and prognosis of gastric cancer [J]. The Journal of Practical Medicine, 2026, 42(7): 1201-1207.
[5]	Chunming WU,Wen CHENG,Zhengguo ZHANG,Yan JIANG,Jun SUN. Relationship between CURB-65 score， serum IL-6， PCT/ALB ratio and prognosis in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2026, 42(6): 923-929.
[6]	Bin YU,Jian ZHOU,Tian TIAN,Fusheng WANG. The efficacy of bevacizumab combined with chemotherapy in the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on mpfs median progression-free survival [J]. The Journal of Practical Medicine, 2026, 42(5): 750-758.
[7]	Zhenggang WANG,Hui XIONG,Ting HE,Xiaojing LIU,Yanhua YE. Serum melatonin and IGFBP3 levels in the diagnosis and prognostic evaluation of age⁃related cataract [J]. The Journal of Practical Medicine, 2026, 42(5): 831-837.
[8]	Jinsong LI,Senxin HUA,Ludan HUANG,Qing SU. Changes in serum levels of NRG-1， CHIT1， Cx43， and MECP2 in patients with acute cerebral infarction and their relationship with severity and prognosis [J]. The Journal of Practical Medicine, 2026, 42(4): 691-697.
[9]	Jianhua JIAO,Ruixue MA,Honghong GU,Xing WU,Xiuli CAO. Evaluation value of sCD163， SHR， pro-ADM， PTX3 combined with score of chest CT on the condition and prognosis of elderly patients with stroke-related pneumonia [J]. The Journal of Practical Medicine, 2026, 42(3): 447-454.
[10]	Jianxia HUANG,Guoliang ZHANG,Jushan ZHANG,Yan WANG,Qing WU,Binzhang WU,Minghu DU,Yuxia WANG. The relationship between levels of serum MuC1， PINP， sFLC and clinical staging， immunophenotyping in patients with multiple myeloma and their predictive value for prognosis [J]. The Journal of Practical Medicine, 2026, 42(3): 504-510.
[11]	Wen LI,Haisheng HUANG,Bin HUANG,Li HAN. Expression correlation of PD⁃L1 and Her⁃2 in invasive urothelial carcinoma and their impact on prognosis [J]. The Journal of Practical Medicine, 2026, 42(2): 194-200.
[12]	Xin LIU,Hongrui ZHANG,Ying SHEN,Yuqiao DIAO,Tao FAN. Correlation of serum lncRNA THRIL， lncRNA NEAT1 with the severity and prognosis of neonatal pneumonia [J]. The Journal of Practical Medicine, 2026, 42(2): 327-333.
[13]	Xuan SUN,Lu XU,Yan GAO,Yingying MA,Jidong ZHAO. The combined predictive value of sFlt-1， Lp-PLA2， MHR and ICAM-1 for the severity and prognosis of diabetic foot ulcers [J]. The Journal of Practical Medicine, 2026, 42(10): 1703-1711.
[14]	Xinghua BIAN,Peng XU,Junfei SHI,Zhenhua MA. The predictive value of serum matrix metalloproteinase-2， myeloperoxidase， axonal guidance factor 3E for the prognosis of patients undergoing intracranial aneurysm clipping surgery under general anesthesia [J]. The Journal of Practical Medicine, 2026, 42(1): 56-63.
[15]	Yingdao CHEN,Haining LI,Yuying LI,Qiping ZHANG,Bingsong LIANG,Guohui. LI. The predictive value of serum miR-143-3p and miR-188-5p levels for poor prognosis in patients with acute cerebral infarction after thrombolysis [J]. The Journal of Practical Medicine, 2025, 41(8): 1117-1122.